Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 13/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 4/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 4/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 4/20 | 1.00 |
| ▸ | ITGB8 | P26012 | 4/20 | 1.00 |
| ▸ | ITGA8 | P53708 | 4/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224650 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL22139457 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6266940 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6682740 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6049848 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6679570 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6221783 | 0.93 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6224073 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6227107 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6226327 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572210-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | claimed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | claimed |
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| EP-1572210-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | disclosed |
| US-20040234624-A1 | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | MCKEARN JOHN P (US) | 2004-11-25 | — | — | US | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | ITGA5, ITGAL, ITGB5 | ITGB3 9/4885ITGAV 4/4885ITGB6 6/4885 |
| US-20040234624-A1 | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | ITGA2, ITGB5, ITGB2 | ITGB3 9/4885ITGAV 11/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.